Stephanie Markovina, MD, PhD studies novel metrics to serve dual purpose as biomarkers for prognosis and response to radiation therapy, as well as therapeutic targets for human solid tumors such as cervical and anal cancers. She studies the role of Squamous Cell Carcinoma Antigen (SCCA), a member of the SERPIN superfamily, and its role in tumor cell resistance to radiation and chemotherapy. Her lab is investigating the role of the lysosome in tumorigenesis and response to anti-cancer therapies. Research goals ultimately are to better stratify of patients prior to initiation of treatment, or early into treatment will allow individualized precision therapy for patients and ultimately better outcomes. Dr. Markovina hopes to understand the molecular role of these biomarkers in cancer pathogenesis and tumor resistance to anticancer treatments such as radiation and chemotherapy, and that this better understanding will lead to identification of novel therapeutic targets.